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283 Can CF patient registries identify pulmonary exacerbations?
G. Sims1,2. 1Australian Clinical Registries, Hawker, Australia; 2Cystic Fibrosis
Australia, Baulkham Hills, Australia
Objectives: To test the internal consistency of markers for pulmonary exacerbations
in cystic ﬁbrosis patient registry data and to validate ﬁndings against clinical
opinion.
Methods: The Australian Cystic Fibrosis Data Registry holds data from individual
occasions of measurement of lung function, episodes of hospitalisation and home
therapy for respiratory indications and results from respiratory cultures. Initial
analysis of 2010 to 2012 data using stata software will identify occasions of
measurement of lung function (FEV1 per cent of predicted) that are 10 per cent or
more below a ‘normal’ level calculated as the patient’s average of highest measures
recorded in each of the preceding four quarters. The temporal relationship of
such occasions with hospital and home therapy episodes for respiratory indications
will permit internal validity checking and sensitivity analysis of the nominated
percentage below ‘normal’. The usefulness of recent prior respiratory cultures as a
potential additional consistency check will also be examined. A sample of results
will be compared with independently formed clinical opinion.
Results: Results are not available at time of abstract submission. They will include
ﬁndings and an outline of methodology.
Conclusion: The occurrence or frequency of pulmonary exacerbations can be a
speciﬁed outcome for clinical trials and is of interest in general research into the
progress of cystic ﬁbrosis. Use of pulmonary exacerbations as an outcome in the
emerging use of CF patient registries for post-market surveillance of long term drug
efﬁcacy requires an understanding of the validity of markers that are available in
registry data.
284 Prevalence of Staphylococcus aureus (SA) infection in patients
with cystic ﬁbrosis in a reference unit
M. Chilet1, A. Herna´ndez-Cabezas2, S. Sancho-Tello1, J.M. Molina2, A. Pastor1,
E. Anso´tegui1, M. Salavert2, J.L. Lo´pez-Hontangas2, A. Sole´1. 1Hospital
Universitari i Polite`cnic La Fe, Lung Transplant and Cystic Fibrosis Unit,
Valencia, Spain; 2Hospital Universitari i Polite`cnic La Fe, Microbiology
Department, Valencia, Spain
Objectives: Epidemiologic, prospective and observational study of infection by
Staphylococcus aureus (SA) in Cystic Fibrosis (CF) patients to evaluate prevalence,
incidence, search for study sensibilities and mechanism resistance and virulence
factors of SA.
Methods: A total of 53 respiratory specimens out of 53 patients in a 5 months period
were obtained (June 2013 to October 2013). Both adults and pediatric patients
were included. Identiﬁcation of colonies was performed with manual techniques
and/or with automatized methods. With the isolation of resulting SA, sensibility
was studied through methods in disc-plate or techniques of microdilution. Detection
of Panton-Valentine leukocidin (PVL) gene was done using PCR in real time.
Phenotypic methods, included coagulase and agglutination tests were performed.
Results: Methicillin-resistant SA (MRSA) was observed in 20.8% (PVL 100%
negative) and methicillin-sensible SA (MSSA) in 79.2% (PVL 26.2% positive) of
isolated. PVL was only detected in patients with MSSA isolated. Prevalence of SA
infection was observed in 18.92% and an incidence in 3.92% in our unit.
Conclusion: We observed a high prevalence of SA in our CF patients unit and
highlight the presence of virulence factors, PVL in our analysis, in MSSA strains.
Therefore every SA has its pathogenic potential.
285 Some cystic ﬁbrosis patients do not tolerate tobramycin
dry powder inhalation
G. Boerner1, S. Prante1, F. Borella2. 1PARI Pharma GmbH, Graefelﬁng, Germany;
2NEUpharma s.r.l., Imola, Italy
Objectives: Tobramycin Inhalation Solutions (TIS) are required in substantial
numbers of cystic ﬁbrosis (CF) patients due to intolerability or incapability to
manage Dry Powder Inhalation (DPI). A market survey was performed to specify
this sub-population.
Methods: This market survey was conducted in Germany (DE) and Italy (IT) with
focus on large CF centres with 50 CF patients.
Results: DPI is used in 18%, TIS in 82% of patients. DPI is primarily used in
adults. Physicians estimated that 1/3 of patients take less DPI treatments than
recommended. Main reasons for non-compliance are side effects as cough and
bronchoconstriction and incorrect inhalation manoeuvres. Reasons for prescribing
TIS are satisfactory tolerance and long-term experience, but also the generalized
beneﬁt of liquid inhalation. Young patients and adults with severe disease beneﬁt
most from TIS. DPI is preferred due to time saving and lower treatment burden.
Adults/workers and patients under time pressure take most advantage of DPI. 90%
of centres have to switch patients from DPI to TIS to overcome side effects.
Conclusion: The survey is regarded representative as the surveyed CF centres
cover about 20% of the CF population in DE and IT. Side effects after DPI are
often rated more serious than a time-consuming TIS treatment, indicating that DPI
is not an ideal treatment for all CF patients, particularly children. A medical need
was identiﬁed for a fast TIS treatment in patients who prefer liquid inhalation for
tolerability reasons.
286 Adult patients with cystic ﬁbrosis exhibit an increasing
prevalence of chronic kidney disease with increasing age,
particularly those with cystic ﬁbrosis-associated diabetes
mellitus and/or an organ transplant
D. Moore1, S. English1, J.A. Eustace2,3, C. Shortt4, B.J. Plant4,5, W.D. Plant3,5.
1School of Medicine, University College Cork, Renal Medicine, Cork, Ireland;
2Clinical Research Centre, University College Cork, Cork, Ireland; 3Department
of Renal Medicine, Cork University Hospital, Cork, Ireland; 4Adult CF Unit,
Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland;
5University College Cork, Cork, Ireland
Objectives: As more patients with cystic ﬁbrosis (PWCF) survive into adult life
the prevalence of other comorbid conditions may increase. Amongst these is
chronic kidney disease (CKD). This is uncommon in children, but is reported with
increasing frequency in adults.
Methods: Retrospective single-centre observational cohort study of 120 adult
PWCF (aged 18−50 yrs) over the period 01/01/11–31/12/12. Patient records were
interrogated to detect evidence of CKD, as deﬁned by the KDIGO 2012 Clinical
Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
Results: 74 (62%) male. Median (IQR) age 27 (21, 31) yrs. On 01/01/11, 25 (21%)
had cystic ﬁbrosis-related diabetes (CFRD). 5 (4%) subsequently developed this.
10 (8%) had received an organ transplant; 4 (3%) received a transplant during the
study period. 5 (4%), all male, died.
13 (11%) patients had CKD on 01/01/13; no new cases developed during the study
period. CKD status was associated (p< 0.05) with increasing age, occurring in
2 (4%) of those <25 yrs, 5 (11%) of those aged 25−34 yrs, and 6 (25%) of those
>34 yrs. Gender was not associated with CKD status. Pre-existing CFRD and/or
an organ transplant was associated (p< 0.05) with CKD status. 7 (23%) of CFRD
patients, and 5 (36%) of those with an organ transplant had CKD. 4 (31%) patients
with CKD had end-stage kidney disease requiring dialysis or renal transplantation.
Of patients who died, one (20%) had CKD.
Conclusion: CKD is a common co-morbidity in this cohort. This increases with
age, and has speciﬁc associated risk factors. This trend may well continue as the
global population of patients with cystic ﬁbrosis ages.
